[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":660},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,257,0,25,[9,47,78,106,131,155,184,214,247,277,306,330,354,374,400,422,446,467,489,509,535,557,584,613,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053547","clinical-trial-for-acupuncture-in-adolescents-with-psychological-distress-and-insomnia-100053547",false,"NCT06638450","Clinical Trial for Acupuncture in Adolescents With Psychological Distress and Insomnia","Dense Cranial Electroacupuncture Stimulation Plus Body Acupuncture for Adolescents With Psychological Distress: a Randomized Controlled Trial With Observations on Salivary Oxytocin and Cortisol Changes","Inclusion Criteria:\n\nParticipants will be eligible for this study if they:\n\n1. are experiencing anxiety as evidenced by a BAI-C score of at least 8 (no symptoms = 0-7; mild = 8-15; moderate = 16-25; severe = 26-63), and\u002For a C-BDI-II score of at least 14 (no symptoms = 0-13, mild = 14-19; moderate = 20-28; severe = 29-63);\n2. have symptoms that have persistent for more than 3 months;\n3. are able to provide informed consent for participation, and complete treatments and questionnaires as scheduled; and\n4. have no suicidal ideation, as evidenced by \"no\" answers or a score of \\\u003C3 for all questionnaires of the Columbia-Suicide Severity Rating Scale (C-SSRS).\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n1. have unstable systemic medical conditions that may limit their participation in the study, for example, severe liver, cardiovascular, or kidney impairment; gastrointestinal or endocrine dysfunction; malignancy; autoimmune disease; acute infectious disease; or any conditions with unstable vital signs or require intensive hospitalization;\n2. have bipolar or psychotic disorder (e.g. schizophrenia);\n3. have a history of brain injury or surgery;\n4. have alcohol abuse or substance abuse;\n5. are pregnant or in lactation, or intend to conceive;\n6. have heart pacemaker or other metal devices implanted in the body;\n7. have concurrent or use of drug treatment for anxiety\u002Fdepression in the previous 6 months;\n8. have treatment with acupuncture or brain stimulation in the previous 6 months;\n9. have a history of epilepsy;\n10. have a condition of bleeding tendency, or coagulopathy, or currently receiving anti-coagulant treatment; or\n11. involved in other interventional clinical studies in the last 3 months or any relevant condition potentially interfering with study evaluation.","ALL","15 Years","22 Years",{"count":21,"type":22},148,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is an assessor-blinded, randomized, MAS-controlled trial. A total of 148 adolescents aged 15-22 years experiencing mild to moderate anxiety or depressive symptoms will be recruited. They will be randomly assigned to DCEAS+BA (n = 74) and MAS (n = 74) for 2 sessions per week for 8 weeks, followed by a 4-week post-treatment observation period. A post-intervention visit will be held at week 12. The primary outcome will be assessed using the Chinese version of the Beck Anxiety Inventory (BAI-C). The secondary outcomes include the Beck Depression Inventory II (C-BDI-II) for depression, the Zung Self-Rating Anxiety Scale (SAS) and the Zung Self-Rating Depression Scale (SDS) as additional assessments for anxiety and depression, the Pittsburgh Sleep Quality Index (PSQI) for sleep quality, and the World Health Organization Quality of Life-Brief (WHOQOL-BREF) (HK version) for the general quality of life. Assessment will be carried out every 4 weeks till week 12, while saliva will be collected at baseline and at the end of the 8 weeks. Salivary oxytocin and cortisol will be analyzed. A generalized linear mixed-effect model will be applied to compare treatment outcomes over time in the two groups and linear regression will be conducted to examine intercorrelations among clinical improvement and changes in biomarker levels. Subgroup analysis will be conducted to identify specific effects of DCEAS+BA.",[28,29],"Psychological Distress","Insomnia",[31,29,32,33],"Psychological distress","Acupuncture","Adolescent","NOT_YET_RECRUITING","2026-07-08",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-07",{"date":42,"type":22},"2028-09",{"name":44,"class":45},"The University of Hong Kong","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100619247","mindfulness-based-lifestyle-modification-programme-for-caregivers-of-people-with-neurological-disorders-100619247","NCT07342140","Mindfulness-based Lifestyle Modification Programme for Caregivers of People With Neurological Disorders","A Brief and Blended Mindfulness-based Lifestyle Counselling Programme (B-Mindful-Life) for Behavioural Risk Modification Among Caregivers of People With Neurodegenerative Disorders: A Randomised Controlled Trial","B-Mindful-Life","Inclusion Criteria:\n\n* Adults who self-identify as the primary co-residing caregivers of ND patients for ≥3 months. ND is defined as any long-term disorder affecting the nervous system, such as stroke, epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, traumatic brain injury, migraines, amyotrophic lateral sclerosis, and Huntington's disease;\n* Experience of at least mild negative emotions, as indicated by DASS-21 score of Depression subscale ≥10, Anxiety subscale ≥8, or Stress subscale ≥15);\n* Have a mobile device (e.g., smartphone, tablet, and laptop) with Internet access; and\n* Able to read and communicate in Chinese and give written consent.\n\nExclusion Criteria:\n\n* Self-reported exercise regimen of great than 150 minutes\u002Fweek of MVPA (according to the American College of Sports Medicine guidelines);\n* Have received (within the past 6 months) or are receiving other physical and\u002For psychosocial interventions;\n* Pregnancy or within 6 months of postpartum; and\n* Presence of contraindications, such as a current diagnosis of psychiatric illness (according to the DSM IV-TR, DSM-V, or ICD-10) or severe comorbidities (e.g., severe hearing, vision, or cognitive impairment) that might limit full participation.","18 Years",{"count":57,"type":22},236,[25],"Over 80% of caregivers for individuals with neurodegenerative diseases (ND) engage in significant risk behaviors, particularly physical inactivity, which increases the risk of cardiometabolic diseases (CMD) by 30% and reduces life expectancy by 4-8 years. Despite the health benefits of maintaining healthy behaviors, awareness of behavioral risk management among healthcare professionals and the public is low, and research on this topic for ND caregivers is limited. Given that physical activity (PA) is the most prevalent modifiable risk factor, timely intervention is essential.\n\nInternational guidelines prioritize PA as a key strategy for caregiver health. However, existing PA interventions often struggle with low compliance due to the physical and emotional challenges caregivers face. Mindfulness-based lifestyle modification might help caregivers better manage physical discomfort, stress, and self-limiting beliefs, thereby supporting sustained PA by improving attentional regulation and psychological flexibility.\n\nThe World Health Organization advocates for non-communicable disease (NCD) prevention through brief lifestyle interventions, such as ecological momentary interventions (EMI), which use mobile messaging (e.g., WhatsApp) to deliver personalized health content. This method is particularly valuable for caregivers who find it difficult to access traditional services due to their responsibilities.\n\nA pilot RCT was conducted to compare B-Mindful-Life to brief lifestyle education program in Chinese neurodegenerative disease caregivers, demonstrating promising acceptability, engagement, and effect for increasing PA (NCT06583018). Therefore, this full-power randomized clinical trial aims to rigorously examine its effectiveness and broader impact on this underserved population with several advancement: (i) broaden the population into all neurological disorder caregivers to test for the generalizability of the B-Mindful-Life program; (ii) conduct a 12-month follow-up to assess long-term effects of B-Mindful-Life intervention in real-life settings; (iii) modify outcome measures for targeted assessment. The primary outcome will measure the change in accelerometer-determined, 10-minute bout moderate-to-vigorous physical activity (MVPA) over a 7-day period from baseline to post-intervention.",[61],"Caregiver",[63,64,65,66,67,68,69,70],"caregivers","behavioral risk","physical activity","mindfulness","ecological momentary","neurological disorders","lifestyle modification","self-care","2026-06-29",{"date":73,"type":38},"2026-07-01",{"date":73,"type":22},{"date":76,"type":22},"2028-05-31",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":46},"100642609","promoting-smoking-cessation-in-the-community-via-quit-to-win-contest-2026-engagement-focused-genai-based-chatbot-for-real-time-smoking-cessation-support-100642609","NCT07649044","Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2026: Engagement-Focused GenAI-based Chatbot for Real-Time Smoking Cessation Support","Building Capacity and Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2026: Real-time Smoking Cessation Instant Messaging Support Using a Engagement-Focused Large Language Model (LLM)-Based Chatbot","QTW2026","Inclusion Criteria:\n\n1. Hong Kong residents aged 18 years or above\n2. Smoke at least one cigarette (including heated tobacco products) per day or use an e-cigarette daily in the preceding 3 months\n3. Able to communicate in Cantonese (including reading and writing Chinese)\n4. Saliva cotinine level ≥30 ng\u002FmL\n5. Intention to quit or reduce smoking\n6. Have WhatsApp installed\n7. Able to use WhatsApp for communication\n\nExclusion Criteria:\n\n1. Smokers who have communication barriers (either physical or cognitive)\n2. Smokers who are currently participating in other smoking cessation programs or services",{"count":87,"type":22},998,[25],"The goal of this trial is to learn if chatbot-based instant messaging works to help smoking cessation in general adult smokers. It will also learn about the experience, attitude, and perception of using an LLM-based chatbot. The main questions it aims to answer are:\n\n1. Will an engagement-focused LLM-based chatbot smoking cessation intervention have a non-inferior validated abstinence rate than the control group?\n2. Will an LLM-based chatbot smoking cessation intervention have a non-inferior self-reported abstinence rate, smoking reduction rate, and smoking cessation services use rate than the control group?\n\nResearchers will compare an LLM-based chatbot smoking-cessation intervention to a human-led instant messaging support group (brief advice based on AWARD and personalised active referral) to determine whether chatbot-based instant messaging support promotes smoking cessation.\n\nParticipants in the intervention group will receive:\n\n1. AWARD advice\n2. Personalised active referral\n3. 12 weeks of chatbot-based instant messaging support (via WhatsApp)",[91],"Smoking Cessation",[93,94,95,96,97],"Large-language model","Chatbot","Smoking cessation","Digital health","Engagement","2026-06-26",{"date":100,"type":38},"2026-06-30",{"date":102,"type":22},"2026-06-27",{"date":104,"type":22},"2028-06-30",{"name":44,"class":45},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":46},"100534526","vericiguat-in-patients-with-coronary-microvascular-dysfunction-causing-stable-chest-pain-v-com-100534526","NCT06239974","Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Inclusion Criteria:\n\n1. Stable recurrent chest pain.\n2. 40 to 75 years old.\n3. Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\\\u003C50% coronary artery stenosis or fractional flow reserve \\>0.8).\n4. Stress CMR MPR \\\u003C2.19 12 or Stress MBF \\\u003C2.19ml\u002Fg\u002Fmin 13.\n5. Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.\n\nExclusion Criteria:\n\n1. Systolic blood pressure \\\u003C100 mm Hg.\n2. Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).\n3. Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.\n4. On long-acting nitrates (eg. isosorbide mononitrate)\n5. Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis.\n6. Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)) or coronary revascularization (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) within 60 days prior to randomisation, or indication for coronary revascularization at time of randomisation.\n7. Has symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days prior to randomisation.\n8. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n9. Malignancy or other non-cardiac condition limiting life expectancy to \\\u003C3 years.\n10. Patient's with implanted devices which are not MRI compatible.","40 Years","75 Years",{"count":116,"type":22},94,[25],"This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.",[120],"Chest Pain",[122],"Stress Cardiac Magnetic Resonance","RECRUITING","2026-06-25",{"date":71,"type":38},{"date":127,"type":38},"2024-09-01",{"date":129,"type":22},"2027-08-31",{"name":44,"class":45},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":46},"100641024","a-20-year-follow-up-of-first-episode-psychosis-longitudinal-effects-of-early-treatment-strategies-and-relapse-100641024","NCT07616999","A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse","Navigating the Longitudinal Effects of Early Treatment Strategies and Relapse on Clinical, Cognitive, and Functional Outcomes: A 20-Year Follow-up of First Episode Psychosis","Participants were individuals who previously participated in a randomized controlled trial investigating medication continuation\u002Fdiscontinuation on relapse during first episode psychosis (ClinicalTrials.gov NCT00334035). The trial included specific inclusion and exclusion criteria, detailed as follows:\n\nInclusion Criteria:\n\n* A diagnosis of schizophrenia or non-affective psychosis (schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise specified) (DSM-IV)\n* Aged 18 to 65 years at the time of original enrolment\n* Had been treated with antipsychotic drugs for at least 12 months\n* No history of relapse or exacerbation or had to be asymptomatic (free of positive symptoms of psychosis) at study entry.\n\nExclusion Criteria:\n\n* A diagnosis of drug-induced psychosis\n* Current treatment with clozapine, with mood stabilizing medications (lithium, valproate or carbamazepine) or with depot medication\n* Had high risk of suicide or violence\n* Inability to provide informed consent at recruitment","65 Years",{"count":140,"type":22},178,"20 Years","OBSERVATIONAL","The study aims to address the following questions:\n\n1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes?\n2. What are the long-term cognitive functioning trajectories, what factors predict these trajectories, and how do they relate to outcomes?\n3. What might be the mechanisms behind medication discontinuation and poor long-term outcome, including the roles of multiple relapses and treatment resistance after first-episode psychosis?\n\nEligible patients will be invited to a one-time face-to-face interview. A trained research assistant will guide the participants through questions about their background, clinical symptoms, daily functioning, cognitive abilities, and psychological well-being.",[145],"Schizophrenia",[145,147],"20-year follow up","2026-06-23",{"date":98,"type":38},{"date":151,"type":38},"2026-05-21",{"date":153,"type":22},"2028-12-31",{"name":44,"class":45},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100590437","comparative-effects-of-two-oral-antiseptics-used-as-an-adjuvant-in-the-treatment-of-periodontitis-100590437","NCT06967402","Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis","Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis","Inclusion Criteria:\n\n* Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar.\n* Generalized stage II-III periodontitis patients.\n* Baseline BOP \\> 25%.\n* No known allergy or adverse effects to CHX or CPC\n* Non-smokers, non-orthodontic patients, no concurrent or past antibiotics\u002Fmedication known to affect periodontal status (i.e. calcium antagonists, phenytoin)\u002Fanti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant\u002Fbreastfeeding, compliance to study procedures.\n* ASA class I-II patients.\n* Either non-diabetic or with controlled diabetes (HbA1C\\\u003C7).\n* Normal\u002FElevated blood pressure (AHA - Systolic \\\u003C130mmHg; Diastolic \\\u003C80mmHg).\n* No radiation\u002Fchemotherapy in the past 5 years\n* No immunosuppression including drug induced immunosuppression.\n* No participation in other clinical studies in the last 4 weeks.\n* No administration of CHX or CPC in the last 3 months\n* No periodontal treatment in the last 3 months.\n\nExclusion Criteria:\n\n* Unable to provide written consent.\n* Non-compliant study procedures.\n* Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol.\n* Patients requiring antibiotics prophylaxis for dental procedures.\n* Patients with self-reported pregnancy or patients who are breastfeeding.\n* Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months.\n* Patients with uncontrolled endocrine disease.\n* Patients who are not compliant with the review protocol, leading to deviation of more than 1 week.\n* Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.",{"count":163,"type":22},60,[25],"The focus of this study is on two types of mouthwashes - one containing a chlorhexidine (CHX) at 0.2% (CHX), and the other one containing CHX at a lower concentration of 0.12% with cetylpyridinium chloride (CPC). Both mouthwashes are used to help in the treatment of gum disease. CHX has been known for a long time for its effectiveness against plaque and mouth inflammation. It could inhibit and even kill them. However higher concentrations of CHX comes with unwanted side effect including altered taste, teeth staining and irritation in the mouth. Interestingly, these side effects seem to occur less frequently when a lower concentration CHX solution is used. CPC also combats bacteria by adhering quickly to the surfaces inside your mouth, although it has less substantivity than CHX, it has been shown to reduce plaque and gum inflammation effectively, and it typically causes fewer side effects than CHX. We hypothesize that this new formulation of CHX 0.12%+CPC mouthwash is non-inferior to CHX 0.2% in terms of its anti-plaque and anti-inflammatory properties while presenting with less side effects after 21 days of use. Microbiological samples and fluids from periodontal pockets will be collected before and after treatment for analysis of microbiological effects.",[167,168,169],"Periodontitis","Periodontitis Stage II","Periodontitis Stage III",[171,172,173,167,174,175,176],"Mouthwash","Chlorhexidine","CPC","Mouthrinse","cetylpyridinium chloride","Oral antiseptic","2026-06-21",{"date":148,"type":38},{"date":180,"type":38},"2025-11-20",{"date":182,"type":22},"2027-12-31",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":193,"maxAge":18,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100641173","effectiveness-of-vr-on-the-sustainability-of-hand-hygiene-compliance-school-based-rct-with-10-month-follow-up-100641173","NCT07659340","Effectiveness of VR on the Sustainability of Hand Hygiene Compliance: School-based RCT With 10-month Follow-up","Effectiveness of Immersive and Embodied Enhancement Via \"Virtual Reality\" on the Sustainability of Hand Hygiene Compliance: School-based RCT With 10-month Follow-up","HKU-VR-2026","Inclusion Criteria:\n\n* Hong Kong secondary school students studying junior forms\n\nExclusion Criteria:\n\n\\-",true,"12 Years",{"count":195,"type":22},500,[25],"This study aims to evaluate the effectiveness of a VR intervention on teaching handwashing skills which are promoted by the Centre for Health Protection, Department of Health, HKSAR. A 7-step handwashing approach will be taught through a customized VR game in secondary schools in Hong Kong. Participant's handwashing skills and prolonged effects on handwashing habits and hygiene level will be assessed.\n\nThe main questions it aims to answer are:\n\n* Does an intervention of our VR handwashing game enhance handwashing skills amongst junior secondary students?\n* What are the factors hinder or enhance students' learning of handwashing skills in the intervention?\n\nParticipating students will be assigned into 3 groups. Each group will receive two sessions of educational training with different kinds of intervention throughout one school year (9 months). The first intervention group will participate in two VR-game sessions on handwashing skill; the second intervention group will participate in one VR-game session and one video session about handwashing; the baseline group will participate in two sessions of other VR activities unrelated to hand hygiene and view a handwashing skill poster. The research will compare the handwashing performance between the three groups.\n\nParticipants will:\n\n* participate into a VR handwashing game intervention, or a video-based intervention, or placebo VR activities as stated hereinafter;\n* perform handwashing in the VR game, and their hand-motion data will be captured;\n* participate a UV lighting test after handwashing away fluorescent lotion; and,\n* fill up questionnaires",[199,200],"Hand","Hygiene Practices and Knowledge",[202,203,204,205],"Hand Hygiene","Virtual Reality","Hand Disinfection","Educational","2026-06-19",{"date":208,"type":38},"2026-06-24",{"date":210,"type":38},"2026-03-01",{"date":212,"type":22},"2027-08-30",{"name":44,"class":45},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":226,"conditions":227,"keywords":234,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":46},"100644172","phase-3-liposomal-bupivacaine-plus-plain-bupivacaine-versus-dexamethasone-plus-plain-bupivacaine-in-the-supraclavicular-brachial-plexus-block-in-patients-with-risk-factors-for-severe-acute-postoperative-pain-100644172","NCT07665762","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain: a Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologist (ASA) status I-III\n* Age 18-90 years old\n* Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)\n* Informed consent obtained\n* Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:\n\n  * Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6\u002F10 with arm movements at day before surgery.\n  * Preoperative use of opioid: use of strong opioids such as morphine, oxycodone\n  * Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above\n  * Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above\n  * Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant\n\nExclusion Criteria:\n\n* Revision surgery\n* Previous fractures or surgery in the affected distal radius\n* Surgery involving more than the affected arm\n* Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100\n* Respiratory compromise (requires long term oxygen)\n* History of seizures\n* Pre-existing neurological disorder\u002Fdeficit\n* Alcohol or substance abuse\n* Impaired mental state\n* Local infection\n* Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids\n* Impaired renal function (defined as effective glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m2\n* Impaired liver function (defined as plasma bilirubin over 34μmol\u002FL; international normalized ratio \\[INR\\] ≥1.7, alanine aminotransferase \\[ALT\\] over 100U\u002FL, aspartate aminotransferase \\[AST\\] over 100U\u002FL)\n* Coagulopathy (platelet count \\\u003C100,000\u002Fml and\u002For INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB\n* Pregnancy\n* Patient refusal for regional nerve blocks\n* Patient refusal to join the clinical trial\n* Patient unable\u002Funwilling to attend post-op rehabilitation programme","90 Years",{"count":223,"type":22},90,[225],"PHASE3","The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.\n\nA randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and\u002For higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.",[228,229,230,231,232,233],"Pain, Postoperative","Liposomal Bupivacaine","Dexamethasone","Supraclavicular Brachial Plexus Block","High Risk Factors","Distal Radial Fracture",[235,236,237,238,239],"supraclavicular brachial plexus block","liposomal bupivacaine","dexamethasone","distal radial fracture","pain","2026-06-18",{"date":208,"type":38},{"date":243,"type":22},"2026-06-15",{"date":245,"type":22},"2029-03-01",{"name":44,"class":45},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":141,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":258,"conditions":259,"keywords":265,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":46},"100644448","wearable-assessment-of-thoracic-cardiac-health-and-exercise-performance-trial-prospective-100644448","NCT07663799","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)","WATCH-XP","Inclusion Criteria:\n\n* Age 20 to 70 years old\n* Ability to provide informed consent\n* History of the following cardiovascular conditions:\n* Adult congenital heart disease\n* Pulmonary hypertension\n* Heart failure\n* Coronary artery disease\n* Athletes undergoing cardiovascular assessment\n\nExclusion Criteria:\n\n* Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)\n* Pregnancy\n* Known allergy to components of the investigational product","70 Years",{"count":257,"type":22},20,"Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.\n\nThe Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.\n\nThis investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.",[260,261,262,263,264],"Congenital Heart Disease","Pulmonary Hypertension","Heart Failure","Coronary Heart Disease (CHD)","Apple Watch",[266,267,268,269,270],"apple watch","congenital heart disease","heart failure","coronary heart disease","pulmonary hypertension","2026-06-16",{"date":148,"type":38},{"date":274,"type":22},"2026-08-01",{"date":153,"type":22},{"name":44,"class":45},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":46},"100607998","mindful-breath-for-people-with-copd-100607998","NCT07195838","Mindful-Breath for People With COPD","Effects of a Hybrid, Personalised Mindfulness-optimised Pulmonary Rehabilitation (Mindful-Breath) Programme for Active Living for People With Chronic Obstructive Pulmonary Disease: A Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Age: 50-80 years\n* Sex: Male or female\n* Education level: Primary or above\n* Diagnosis: COPD (Baseline FEV1 \\\u003C80% and FEV1\u002FFVC \\\u003C70% of predicted normal values)\n* Severity of COPD: Stage I to IV\n* Group of COPD: Group B, or E, based on 2024 GOLD guideline (36)\n* Clinical stability: No acute exacerbation in the past 4 weeks. Patients with recent acute exacerbation in the past 4 weeks will be screened again in subsequent follow-up.\n* Moderate stress: PSS score ≥14 (28)\n* Access to a mobile device (e.g., a smartphone, tablet, or laptop) with internet connectivity\n* Ability to read, communicate, and provide written consent in Chinese.\n\nExclusion Criteria:\n\n* Engaging in \\>60 minutes\u002Fweek of moderate PA based on American Lung Association guidelines\n* Recent or ongoing receipt of other pharmacological\u002Fbehavioral trials within the past 3 months\n* Contraindications or severe comorbidities that may limit full participation (mental diseases, deafness, limb activity disorder, coronary heart disease, arterial aneurysm, uncontrolled hypertension, pregnancy, etc)\n* Co-existing respiratory diseases (Asthma\u002Finterstitial lung disease\u002Fbronchiectasis) or active malignancies\n* Very severe COPD requiring long-term oxygen therapy or home non-invasive ventilation","50 Years","80 Years",{"count":163,"type":22},[25],"Individuals living with chronic obstructive pulmonary disease (COPD) often suffer from stress and behavioral risks such as physical inactivity. In an attempt to promote healthy behaviors and overall wellbeing among this particular population, this study aims to develop and evaluate a personalized Mindful-Breath intervention combining telehealth technology and mindfulness for COPD patients. This is an assessor-blinded, two-arm exploratory randomized controlled trial with a sequential mixed-method design. A total of 60 participants will be recruited and randomly assigned to either intervention or control group using 1:1 ratio. Intervention group will go through 8 weekly 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. Personalized mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period will also be provided. Control group will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification and will only receive reminder messages for follow-ups. Variables such as time spent on physical activity, lung function, perceived stress, symptom burden and health-related quality of life will be collected at three time-points (T0: baseline, prior to randomization; T1: immediate post-intervention; T2: 3-month post-intervention).",[290,291,292],"Mindfulness","Pulmonary Rehabilitation","Chronic Obstructive Pulmonary Disease (COPD)",[66,294,295,296,69,297,298,299],"pulmonary rehabilitation","chronic obstructive pulmonary disease","RCT","mHealth","EMI","physical inactivity",{"date":271,"type":38},{"date":302,"type":38},"2025-09-30",{"date":304,"type":22},"2027-06-30",{"name":44,"class":45},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":46},"100642038","gen-ai-powered-behavioral-support-plus-chewing-gum-intervention-for-construction-workers-who-smoke-100642038","NCT07649018","Gen AI Powered Behavioral Support Plus Chewing Gum Intervention for Construction Workers Who Smoke","Build to Quit 「築建無煙」: Gen AI Powered Behavioral Support Plus Chewing Gum Intervention for Construction Workers Who Smoke: A Pragmatic, Pilot, Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Hong Kong residents aged 18 or above\n2. Smoke at least one cigarette per day in the preceding 3-month\n3. Able to communicate in Cantonese (including reading and writing Chinese)\n4. Saliva cotinine 30 ng\u002Fml or above\n5. Intent to quit \u002F reduce smoking\n6. Have instant messaging tool (WhatsApp) installed\n7. Able to use instant messaging tool (e.g., WhatsApp) for communication.\n\nExclusion Criteria:\n\n1. Smokers who are participating in other smoking cessation programmes\n2. Smokers who are using any smoking cessation medication\n3. Smokers who are presenting with the following oral diseases, including recent oral surgery or tooth extraction, unstable dentures, significant tooth mobility or advanced periodontal disease, temporomandibular pain or dysfunction, or painful oral mucosal lesions",{"count":314,"type":22},200,[25],"The goal of this pilot trial is to learn if 1-week NRT sampling, 3-week chewing gum, and 12-week chatbot-delivered instant messaging support works to help smoking cessation in construction workers who smoke. It will also learn about the feasibility, acceptability, and preliminary effectiveness of delivering the comprehensive intervention in construction settings. The main questions it aims to answer are:\n\n1. Will the integrated intervention, comprising NRT sampling, chewing gum, and chatbot-delivered instant messaging support, show feasibility, acceptability, and appropriateness for delivery in construction worksite settings?\n2. Will participants who receive the comprehensive intervention have a higher validated abstinence rate than those who receive NRT sampling alone?\n\nResearchers will compare the integrated intervention, comprising NRT sampling, chewing gum, and chatbot-delivered instant messaging support, to the standard care group (NRT sampling alone) to see if the integrated intervention works to promote smoking cessation.\n\nParticipants in the intervention group will receive:\n\n1. AWARD advice and brief video\n2. 1-week NRT sampling\n3. 3-week chewing gum\n4. 12-week chatbot-based instant messaging support (via WhatsApp)",[91],[319,320,94,321,96,322],"Nicotine replacement therapy","Chewing gum","Large Language model","Construction worker","2026-06-14",{"date":325,"type":38},"2026-06-17",{"date":327,"type":22},"2026-06-20",{"date":304,"type":22},{"name":44,"class":45},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":114,"enrollmentInfo":336,"targetDuration":338,"studyType":142,"phases":4,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":46},"100497860","screening-for-lung-cancer-in-subjects-with-family-history-of-lung-cancer-100497860","NCT05762731","Screening for Lung Cancer in Subjects With Family History of Lung Cancer","Inclusion Criteria:\n\n* Age 50-75, men or women, smokers or non-smokers\n* Being first degree relatives (Siblings, children, and parents) of lung cancer subjects\n* Having no known lung cancer before\n\nExclusion Criteria:\n\n* Non-Chinese\n* Mentally incompetent to give informed consent",{"count":337,"type":22},1520,"3 Years","Lung cancer can be detected via screening of high-risk individuals, i.e current or ex-heavy smokers, with low-dose computer tomography (LDCT) of thorax. The National Lung Screening Trial in US and the NELSON trial in Europe demonstrated reduction in lung cancer mortality with LDCT screening for lung cancer. In Hong Kong, however, there is a prominence of female never-smokers with lung cancer. There is no identifiable risk factors for non-smokers with lung cancer except family history of lung cancer. The hypothesis is that lung cancer screening for subjects with family history of lung cancer, can detect early lung cancer.",[341],"Lung Cancer",[343,344,345],"Lung cancer","Screening","Family history","2026-06-07",{"date":348,"type":38},"2026-06-09",{"date":350,"type":38},"2023-02-01",{"date":352,"type":22},"2028-05",{"name":44,"class":45},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":46},"100643413","effects-of-concurrent-and-consecutive-repetitive-transcranial-magnetic-stimulation-rtms-and-cognitive-bias-modification-cbm-100643413","NCT07636694","Effects of Concurrent and Consecutive Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive Bias Modification (CBM)","TMS CBM","Inclusion Criteria:\n\n* Aged 18 years or above\n* Right-handed\n* Normal or corrected hearing and vision\n* Obtained primary education or above\n* Able to fluently read and understand Chinese\n* Beck's Depression Inventory-II (BDI-II) score ranging from 14-28\n\nExclusion Criteria:\n\n* History of severe physical disease, brain organic diseases, and neurological disorders (e.g., dementia, brain injury, stroke, epilepsy, Parkinson's disease)\n* History of substance use\u002F dependence\u002F withdrawal\n* Participants with intellectual disability based on IQ scores\n* Participants with contraindications for rTMS such as foreign metal bodies, implant devices (cochlear implants) or history (personal or family) of seizure\n* Participants who are not suitable to be scanned by magnetic resonance imaging (MRI) machine (e.g., claustrophobic, pregnant, metal in the body, hearing aids)",{"count":362,"type":22},180,[25],"The goal of this study is to learn whether combining repetitive transcranial magnetic stimulation (rTMS) with a computerized behavioral intervention (imagery cognitive bias modification, CBM-I) reduces negative interpretation bias and mild-to-moderate depressive symptoms. The study will also examine neural changes in the dorsolateral prefrontal cortex (DLPFC) and whether timing of interventions affects outcomes.\n\nThe main questions it aims to answer are:\n\nDoes active TMS reduce negative interpretation bias and depressive symptoms more than sham TMS? Is delivering CBM-I concurrently with TMS more effective than delivering it consecutively (separate sessions) at reducing negative bias and depressive symptoms? Do combined rTMS + CBM-I approaches produce greater neural changes and improved cognitive control over self-referential interpretation than controls? Researchers will compare active TMS versus sham TMS, and concurrent versus consecutive delivery of CBM-I, to test effects on negative bias and depressive symptoms.\n\nParticipants will:\n\nReceive either active rTMS or sham TMS targeting the DLPFC Complete imagery CBM-I sessions either concurrently with TMS or in separate (consecutive) sessions Undergo assessments of negative interpretation bias, depressive symptoms, and neural measures before and after the intervention",[366],"Depression - Major Depressive Disorder","2026-06-04",{"date":348,"type":38},{"date":370,"type":38},"2025-02-24",{"date":372,"type":22},"2028-12",{"name":44,"class":45},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":381,"maxAge":285,"enrollmentInfo":382,"targetDuration":383,"studyType":142,"phases":4,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":46},"100643349","ctdna-mutations-and-methylation-status-for-early-detection-of-lung-cancer-in-patients-with-suspicious-lung-nodules-100643349","NCT07615556","ctDNA Mutations and Methylation Status for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Circulating Tumor DNA Mutations and Methylation Status as Biomarkers for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Inclusion Criteria:\n\n1. Age 45 - 80 years;\n2. Suspicious lung nodules (\\> 0.5 - 30mm in longest diameter, non-calcified) found within the past six months, or if PET scan has been done before, the specific uptake value (SUV) should be more than 1\n\nExclusion Criteria:\n\n1. Age \\\u003C 45 or \\> 80;\n2. Lung nodules of \\\u003C 0.5 cm in longest diameter, or with calcification seen in imaging;\n3. Known lung cancer or lung metastasis before, or history of extra-pulmonary cancer;\n4. Active tuberculosis;\n5. Clinical unstable conditions including untreated ischemic heart disease or arrhythmia, uncontrolled airway disease;\n6. Unwillingness to undergo invasive investigation like bronchoscopy;\n7. Unable to provide informed written consent.","45 Years",{"count":314,"type":22},"2 Years","Lung Cancer is common in Asia and is different from lung cancer from Western countries in terms of lung cancer epidemiology and management. Lung cancer can be detected early but most early-stage lung cancer appear as lung nodules with suspicious features on imaging. Workup and surveillance for subjects with suspicious lung nodule is a clinical problem. There is no consensus and clinical practice usually varies with local epidemiology of lung diseases namely the local clinical characteristics especially with lung cancer and pulmonary tuberculosis. The clinical challenge is to address whether pulmonary nodules identified on CT screening carry short- and long-term risk for lung cancer. The main objective of this study is to test the improvement of efficiency of diagnostic evaluation with clinical parameters and ctDNA mutation\u002Fmethylation profiling for artificial intelligence modeling of for early detection of lung cancer in subjects with suspicious lung nodules. The hypothesis is that ctDNA mutation and methylation will enhance early detection of lung cancer in patients with suspicious lung nodules. This is a longitudinal cohort study. A total of 200 subjects (100 from Hong Kong and 100 from Vietnam) with suspicious lung nodules on CT Thorax will be recruited. Blood samples will be collected at recruitment and subsequent 6 months follow up. ctDNA mutations and methylation with SPOTMAS Lung assays would be performed at baseline and at 6 months follow-up. The CT scan where the suspicious lung nodules were identified, will be used as baseline scan for recruitment. Recruited subjects will be arranged with a non-contrast LDCT scans at 6 months follow-up. The primary outcome measure of the study is the detection of ctDNA mutation and methylation in correlation with diagnosis of lung cancer or persistence of suspicious lung nodules. The secondary outcome measures of the study are the Sensitivity and specificity of clinical biomarkers in correctly identifying malignant lung nodule, i.e., lung cancer.",[386,387,388],"Lung Nodules","Lung Cancer Screening","Suspected Lung Cancer",[390,391,392,393],"ctDNA mutation","Methylation status","Early detection of lung cancer","Suspicious lung nodules",{"date":395,"type":38},"2026-06-08",{"date":397,"type":22},"2026-06",{"date":372,"type":22},{"name":44,"class":45},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":46},"100641033","digital-heart-rate-variability-biofeedback-intervention-for-first-episode-psychosis-100641033","NCT07628699","Digital Heart Rate Variability Biofeedback Intervention for First Episode Psychosis","Digital Heart Rate Variability Biofeedback Intervention for First Episode Psychosis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with first-episode-psychosis who have been in treatment for less than 5 years\n* Inclusive of affective and non-affective psychosis\n* Aged 18-55\n* A diagnosis of schizophrenia-spectrum disorders or affective psychosis including schizoaffective disorder, bipolar affective disorders and depression with psychosis based on DSM V diagnostic criteria\n* Able to provide written informed consent.\n* Patients should be stable but with symptoms present\n* Score a minimum of 7 on the Calgary Depression Scale.\n\nExclusion Criteria:\n\n* Any organic neurological or cardiac conditions\n* Prescription of cardiovascular medication\n* Active severe suicidal ideation\n* Diabetes as this can affect HRV\n* Current substance abuse\n* An ECG will be performed on each participant prior to joining the study to exclude undiagnosed cardiac conditions","55 Years",{"count":409,"type":22},80,[25],"The objective of the current study is to assess the impact of a five-week digital heart rate variability biofeedback (HRV-B) intervention or music listening on the well-being of first episode psychosis patients. Heart rate variability (HRV) is a measure of how an individual's heart rate can adapt to a changing environment and mental and physiological challenges. It has been well established that HRV can be regulated through actions such as slow breathing and meditation. HRV Biofeedback (HRV-B) involves breathing at a specific frequency, usually around 6 breaths per minute, which has been shown to maximize HRV. Research has shown that HRV-B interventions improved mental health symptoms in various populations including individuals at clinical high risk for psychosis.",[413],"First Episode Psychosis (FEP)","2026-06-02",{"date":416,"type":38},"2026-06-05",{"date":418,"type":22},"2026-06-01",{"date":420,"type":22},"2026-08",{"name":44,"class":45},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100637537","dentine-hypersensitivity-using-dentine-adhesive-with-strontium-doped-bioactive-glass-ceramic-100637537","NCT07628712","Dentine Hypersensitivity Using Dentine Adhesive With Strontium-doped Bioactive Glass-Ceramic","Dentine Hypersensitivity Treatment Using Strontium-doped Bioactive Glass-ceramic-filled Dentine Adhesive: a Randomized Double-blind Controlled Clinical Trial","Inclusion Criteria:\n\n* individuals who experienced cervical dentine sensitivity for 1 month or more\n\nExclusion Criteria:\n\n* 1\\) \\\u003C20 teeth; 2) teeth with poor oral hygiene, severe periodontal conditions, with caries, faulty restorations, dentine exposure at the occlusal surface, covered by prosthetics or orthodontic appliances, or undergoing endodontic treatment; 3) currently using or have used any desensitizing agents in the past 3 months; or have undergone restorative treatment on the sensitive tooth; 4) with a severe medical condition or in chronic use of a medication that could have interfered with the perception of pain or any condition\u002Fmedication that causes xerostomia","69 Years",{"count":431,"type":22},142,[25],"The goal of this clinical trial is to determine whether strontium-doped bioactive glass-ceramic (SBGC)-filled dentine adhesive is effective in relieving dentine hypersensitivity. The main question it aims to answer is:\n\nIs SBGC-filled dentine adhesive more effective in reducing dentine hypersensitivity than non-SBGC-filled dentine adhesive?\n\nResearchers will compare SBGC-filled dentine adhesive to a dentine adhesive to see if SBGC-filled dentine adhesive is more effective at relieving dentine hypersensitivity.\n\nParticipants will receive a single application of either SBGC-filled dentine adhesive (intervention group) or dentine adhesive (control group) on the root surfaces of teeth presenting with pain subject to an air-blast test. The degree of pain will be assessed using a Sensitivity Score at baseline, immediately after application of either the intervention dentine adhesive or control dentine adhesive. The participants will visit the clinic at 1 month, 3 months and 6 months for re-assessment of the severity of dentine hypersensitivity.",[435],"Dentine Hypersensitivity",[437,438,439],"dentine hypersensitivity","bioactive glass","resin bonding system",{"date":416,"type":38},{"date":442,"type":22},"2026-05-18",{"date":444,"type":22},"2027-09-30",{"name":44,"class":45},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":192,"sex":17,"minAge":284,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":46},"100453394","proprioceptive-deficits-in-degenerative-cervical-myelopathy-100453394","NCT05183971","Proprioceptive Deficits in Degenerative Cervical Myelopathy","Early Detection of Proprioceptive Dysfunction in Degenerative Cervical Myelopathy by Proprioceptive Functional Analysis in Activities of Daily Living","Inclusion Criteria:\n\n* Chinese\n* Aged 50 or above\n* With radiological evidence of degenerative cervical myelopathy, both symptomatic and asymptomatic\n* Nurick grade less than 3\n\nExclusion Criteria:\n\n* Non-Chinese ethnicity\n* Aged under 50\n* without any radiological proof of cervical myelopathy\n* Active problems of tuberculosis spine, lumbar spinal diseases, and other problems causing pain or deformities over the limbs that may affect their balance and movement\n* Presents with extra-pyramidal or other disorders involving the cerebellum or frontal lobe of the cerebrum leading to poor balance and gait disturbance\n* Previous spinal operation with residual disturbance in balance or gait\n* Non-communicable patients with insufficient cognitive ability to express their symptoms clearly\n* Non-walker\n* Blind or deaf",{"count":454,"type":22},100,"Proprioceptive deficits in degenerative cervical myelopathy (DCM) is a progressive neurological deficits in somatosensory and motor function which affects the body balance and motor control. DCM usually presents with body incoordination, hand clumsiness and gait disturbance associated with proprioceptive dysfunction that hinders the physical performance and functions. In this study, a non-invasive assessment protocol on proprioception will be developed for detecting subtle proprioceptive deficits at the early stage of disease through simple Physical Performance Tests for population older than 45. By adopting the physical performance tests as the diagnostic predictors of DCM, we aim to avoid the development of devastating consequences and disabilities.",[457],"Cervical Myelopathy",[459,460],"Degenerative Cervical Myelopathy","Proprioceptive Deficits",{"date":367,"type":38},{"date":463,"type":38},"2022-09-01",{"date":465,"type":22},"2046-09-30",{"name":44,"class":45},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":481,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":46},"100452558","effects-of-a-machine-learning-based-lower-limb-exercise-training-system-for-knee-pain-100452558","NCT05173064","Effects of a Machine Learning-based Lower Limb Exercise Training System for Knee Pain","Development and Randomized Controlled Trial of an AI-powered Technological Surrogate Physiotherapist (TSP) Dedicated to Quality Enhancement and Cost Reduction in Knee Osteoarthritis Exercise Rehabilitation","Inclusion criteria:\n\n1. At least 50 years of age;\n2. Report having knee pain most days of the week;\n3. Has radiographic evidence of grade 2, 3, or 4 knee OA on the K-L scale in the posteroanterior and\u002For skyline view in at least 1 knee;\n4. Willing and able, both physically and cognitively, to perform the exercises required in the study protocol;\n5. Has normal or corrected-to-normal vision;\n6. Able to speak Cantonese and read Chinese, AND\n7. Able to provide written informed consent.\n\nExclusion criteria:\n\n1. Having a history of knee or hip replacement surgery;\n2. Being nonambulatory;\n3. Having systemic inflammatory arthritis (e.g., gout);\n4. Having a history of trauma (e.g., fractures around the knee, dislocation, sprains or tears of soft tissues like ligaments) or surgical arthroscopy of either knee within the past 6 months;\n5. Having intra-articular injection to the knee within the past 6 months;\n6. Having cognitive impairment;\n7. Involvement in a similar study (i.e., involving physical exercise or physical therapies for knee pain) within the past 6 months;\n8. Undergoing recent or imminent surgery (within 3 months) , OR\n9. Having medical co-morbidities that preclude participation in exercise.",{"count":475,"type":22},176,[25],"The goal of the study is to confirm the idea of AI-powered Technological Surrogate Physiotherapist (TSP), by demonstrating its effectiveness and value as a new technology-based contribution to OA healthcare. Participants will be randomized to one of two groups: (1) the conventional PT group receiving the exercise program delivered through in-person sessions; or (2) the AI-guided group following the program through the TSP after an initial PT session. All individuals will take part in the study for 12 weeks, and data will be collected at baseline and 12 weeks after randomization.",[479,480],"Pain","Knee Osteoarthritis",[482],"knee pain, physical therapy, exercise",{"date":367,"type":38},{"date":485,"type":22},"2026-05-20",{"date":487,"type":22},"2027-09-01",{"name":44,"class":45},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":192,"sex":17,"minAge":4,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":508,"locationsCount":46},"100606695","designing-a-smoking-intervention-for-youth-smokers-100606695","NCT07178899","Designing a Smoking Intervention for Youth Smokers","Designing a Smoking Intervention for Youth Smokers Using Q-Methodology: A Pilot Randomized Controlled Trial","Inclusion Criteria (Phase 1):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Not using cigarettes for the past 7-30 days\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n* Quit smoking without using cessation services\n\nInclusion Criteria (Phase 3):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Received at least 4 weeks of smoking cessation service before enrolling into the study\n* abstained from tobacco use for 7 days without concurrent use of any cessation services\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n\nExclusion Criteria (Phase 1 \\& 3):\n\n* Have unstable physical or psychological conditions as advised by doctors or counsellors\n* Are users of illicit drugs (e.g., heroin, marijuana, ketamine, etc.)\n* Have become pregnant in the past two months\n* unable to communicate in Cantonese and read Chinese\n\nInclusion Criteria (Phase 2) (for SC counsellors) :\n\n* SC counsellors from local SC clinics under HKU Youth Quit Line, Tung Wah Group of Hospitals Integrated Center on Smoking Cessation and United Christian Nethersole Community Health Service","25 Years",{"count":454,"type":22},[25],"This study aims to develop a typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit. The two main research questions include (1) Can a typology-based smoking relapse prevention intervention be feasible and accepted by the smokers and SC counsellors who deliver the new intervention? (2) What is the preliminary evidence on the efficacy of the typology-based smoking relapse prevention to increase tobacco abstinence in ex-smokers who have recently quit? If the intervention shows at least a small effect size (i.e. risk ratio\\>1.3), or the intervention is feasible while modifications can potentially increase the efficacy, a future definitive RCT is warranted.",[501,502,296],"Smoking (Tobacco) Addiction","Young Adult",[91,502,296],"2026-05-29",{"date":414,"type":38},{"date":416,"type":22},{"date":304,"type":22},{"name":44,"class":45},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":517,"briefSummary":518,"conditions":519,"keywords":526,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":46},"100579202","dyadic-mindfulness-for-people-with-parkinsons-disease-and-their-caregivers-100579202","NCT06821230","Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers","Enhancing Psychological Wellbeing and the Patient-caregiver Relationship Through Dyadic Mindfulness: A Randomized Controlled Trial in People With Parkinson's Disease and Their Caregivers","Inclusion Criteria of PwPD:\n\n* Chinese patients with idiopathic mild-moderate PD (as indicated by the Hoehn and Yahr Scale stages I-III: those with unilateral\u002Fbilateral symptoms, with\u002Fwithout postural instability who are able to walk\u002Fstand unassisted)\n* Aged ≥18 years\n\nInclusion Criteria of caregivers of PwPD:\n\n\\- Self-identified as the primary caregivers of their patient\n\nEither patient or caregiver needs to experience at least mild negative emotions (as indicated by the 21-item Depression, Anxiety and Stress Scale \\[DASS21\\] score of Depression subscale ≥10, Anxiety subscale ≥8, or Stress subscale ≥15)\n\nBoth need to be able to communicate in Cantonese and provide written consent.\n\nExclusion Criteria:\n\n* Engage in regular supervised mind-body practices such as Tai Chi, yoga, or other forms of mindfulness training (\\>2 times per week)\n* Have a pre-existing acute psychotic disease\n* Currently participating in any other behavioral or pharmacological trial\n* Have significant cognitive impairment, as indicated by an Abbreviated Mental Test score≤ 6\n* Have other contraindications that may limit their full participation (e.g., severe hearing\u002Fvision impairment)",{"count":314,"type":22},[25],"The proposed two-arm randomized waitlist-controlled trial will use a mixed-methods design to investigate the effects of dyadic mindfulness on physio-psycho-spiritual outcomes in people with Parkinson's Disease (PwPD) and their family caregivers. One hundred Chinese patient-caregiver dyads will be randomized to receive eight weekly 90-minute dyadic mindfulness sessions or usual care. Outcome measures include negative emotions (primary outcome), patient-caregiver relationship, mindfulness, HRQOL, gut microbiome, PD-related symptoms, and caregiving burden. An actor-partner interdependence model will be used to explore the interactions of treatment effects within the dyads. The dyads will be assessed at baseline(T0), post-intervention(T1), and 4-months post-intervention(T2). The investigators will also invite 25 dyads to attend in-depth interviews exploring their experiences, perceived changes, and factors attributable to the effectiveness\u002Fineffectiveness of the intervention. Generalized linear mixed-effects (GLME) with intention-to-treat analysis will be used to compare the changes in outcomes over time within and between the two arms. The findings will be triangulated to provide a comprehensive evaluation of the intervention's effectiveness. This study will generate rigorous scientific evidence to inform the application of dyadic mindfulness as a public health practice preventing the progression of psychological distress in PwPD and caregivers to clinically severe levels. Its self-help nature also enriches the primary care for this clinical cohort.",[290,520,521,522,523,524,525],"Caregivers","Movement Disorders","Neurodegenerative Disease","Dyadic Intervention","Psychosocial Health","Parkinsons Disease",[527,290,528],"Parkinsons disease","dyadic care","2026-05-28",{"date":418,"type":38},{"date":532,"type":38},"2025-02-11",{"date":304,"type":22},{"name":44,"class":45},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":192,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":46},"100523024","motivational-interviewing-to-enhance-advance-care-planning-for-older-adults-and-caregivers-after-emergency-visits-100523024","NCT06090240","Motivational Interviewing to Enhance Advance Care Planning for Older Adults and Caregivers After Emergency Visits","Maximizing Teachable Moments: Motivational Interviewing (MI) to Enhance Advance Care Planning (ACP) for Older Adults and Caregivers After Emergency Visits - A Mixed-Method Randomized Controlled Trial","The target group will be dyads comprising older adults who have had ER visits within the previous six months and their family caregivers. A dyad is defined as one older adult and one primary family caregiver of the older adult.\n\nFor older adults:\n\nInclusion Criteria:\n\n* Aged 65 or older\n* At least one episode of ER visit in the last six months\n* Has a family caregiver to be present during the intervention\n* Able to communicate in Chinese\n\nExclusion Criteria:\n\n* Has completion of an AD\n* Moderate to severe cognitive impairment or diagnosis of dementia, as identified in health records\n* Communication problems (e.g., deafness or aphasia)\n\nFor family caregivers:\n\nInclusion Criteria:\n\n* Aged 18 or above\n* Immediate or extended family member or friend nominated by an eligible older adult participant as primary caregiver\n* Able to communicate in Chinese\n\nExclusion Criteria:\n\n* Moderate to severe cognitive impairment\n* Communication problems (e.g., deafness or aphasia)",{"count":543,"type":22},300,[25],"This study aims to evaluate the effectiveness of a motivational interviewing (MI) intervention in enhancing advance care planning (ACP) among older adults who have visited the Emergency Room (ER) in the past six months and their family caregivers. The main question it aims to answer is: The effectiveness of the MI-based ACP intervention implemented within six months of an ER visit on improving older adults' advance directives (AD) completion rate.\n\nCompared to participants in the control group who will only receive a self-education booklet, participants in the intervention group will receive a motivational interview educational intervention to see the effectiveness of an MI-based ACP intervention implemented within six months following an emergency room visit regarding the completion of AD for older adults.",[547,548,549,550],"Older Adults","Advance Care Planning","Advance Directives","Family Members",{"date":414,"type":38},{"date":553,"type":38},"2023-12-14",{"date":555,"type":22},"2027-07-31",{"name":44,"class":45},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":192,"sex":17,"minAge":113,"maxAge":564,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":46},"100640983","osteoporosis-and-sarcopenia-prevention-in-middle-aged-population-100640983","NCT07611097","Osteoporosis and Sarcopenia Prevention in Middle-Aged Population","FORTIFY","Inclusion Criteria:\n\n* General Population: Women and men aged 40-60 years, defined as age groups where the rate of injuries were still relatively lower, thus considered as a low to moderate risk cohort for osteoporosis.\n* Risk profile: Targets a low to moderate risk cohort for osteoporosis (e.g., as defined by no prior fragility fracture and questionnaire). This aligns with the study's primary prevention objective.\n* Individuals with well-controlled comorbidities like hypertension, diabetes, or pre-diabetes can be included in the study program. Exercise and healthy nutritional diets can also help treat their existing health conditions.\n\nExclusion Criteria:\n\n* Significant comorbidities: Individuals with existing (e.g., severe or uncontrolled) medical illness, due to risk to aerobic exercise. This includes, but is not limited to, active ischemic heart disease, unstable angina, uncontrolled hypertension, or other conditions as determined by study physicians.\n* High baseline activity: Individuals who have engaged in \\>4 hours intensive sports per week will be excluded. This population is deemed to be at very low risk, thus would likely derive minimal additional benefit from the intervention, and their inclusion could represent inefficient use of finite resources (e.g., DEXA scanning services).","60 Years",{"count":566,"type":22},8336,[25],"This initiative is designed to yield substantial and multi-level benefits for the Hong Kong community by pioneering a transformative model of preventive healthcare. It represents the largest randomized controlled trial for osteoporosis and sarcopenia prevention in the region, adopting a comprehensive approach to fracture prevention through innovative fitness, lifestyle, and digital strategies.\n\nThe study's primary objective is to evaluate the efficacy of preventing fractures, osteoporosis, and sarcopenia through an incentivized program of fitness and lifestyle modifications in adults aged 40-60. The secondary objectives include: (1) to validate the use of simple, low-cost measures (grip strength and InBody body composition analysis) as reliable proxy indicators for osteoporosis and sarcopenia risk relative to the gold-standard DEXA scan; (2) to develop a formal, standardized clinical protocol for early detection and prevention, including specified DEXA anatomical measurement sites, for use by healthcare professionals in primary and community care settings; (3) to assess changes in exercise behavior, musculoskeletal health, physical function, health literacy, and participant engagement with the digital (AI chatbot) support system; (4) to analyze the cost-effectiveness of the intervention compared to standard care or pharmacological treatment, including an assessment of healthcare utilization and Quality-Adjusted Life Years (QALYs).\n\nAfter baseline screening and consent, participants are randomly assigned to one of two groups (1:1 ratio) with intention-to-treat principles. The Control Group will receive passive, static support. This involves participating in one initial FUN Day, receiving standard exercise videos, using a passive chatbot for data reporting, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving souvenirs at the study start and end. Meanwhile, the Intervention Group will receive active, dynamic support designed to build and reinforce healthy habits. This involves participating in the initial FUN Day, a reinforcement FUN Day at 2 months, nine mandatory structured exercise touchpoints, using an active chatbot with reminders, feedback, and gamification, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving ongoing incentives and souvenirs at multiple points. Therefore, researchers will compare between the control and intervention groups to see if intervention can prevent osteoporosis and sarcopenia at a population level.\n\nAll participants will undergo a series of assessments at specific timepoints. This includes two DEXA scans (at the study start and in the fourth year, requiring a participant co-payment), InBody composition analysis, and physical health assessments (e.g., grip strength, balance, cardiovascular fitness). These assessments will be performed at baseline (during the first FUN Day), 3 months, 12 months, 24 months, and 36 months. A long-term follow-up will continue for up to 10 years to monitor adverse health events such as falls and fractures. Participants will also complete questionnaires via an AI chatbot at baseline, 3 months, and annually during follow-up. The collected data will encompass health literacy (e.g., osteoporosis\u002Fsarcopenia knowledge scores), digital engagement (e.g., chatbot responsiveness), and economic outcomes (e.g., incremental cost per Quality-Adjusted Life Year \\[QALY\\] gained). Data analysis will employ appropriate statistical methods to compare outcomes between the control and intervention groups across all assessments and timepoints.",[570,571],"Osteoporosis","Sarcopenia",[573,574,575,576,577,578],"Randomized Controlled Trial","Middle-Aged Population","Osteoporosis Prevention","Sarcopenia Prevention","AI Chatbot","DEXA Alternative",{"date":529,"type":38},{"date":418,"type":22},{"date":582,"type":22},"2036-05-31",{"name":44,"class":45},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":599,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":612},"100617211","acupressure-for-cough-in-lung-cancer-survivors-100617211","NCT07315672","Acupressure for Cough in Lung Cancer Survivors","Acupressure for Cough in Lung Cancer Survivors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* be at least 18 years of age;\n* have a diagnosis of LC at any stage and of any pathological type;\n* have a cough symptom rating ≥3 on a 0 to 10 numeric rating scale within 7 days preceding enrollment;\n* can perform acupressure independently in daily activities;\n* be able to read Chinese and communicate in Cantonese or Mandarin;\n* be able to provide informed consent.\n\nExclusion Criteria:\n\n* have unstable chronic diseases other than LC;\n* have received acupressure or acupuncture within the three months preceding study enrollment;\n* have serious illnesses or other conditions that prevent the participants from following the intervention protocols;\n* have a life expectancy of less than 3 months;\n* Be currently participating in other research programs that may affect the outcomes under investigation.",{"count":409,"type":22},[25],"The goal of this randomized controlled trial is to examine the effect of an acupressure intervention in alleviating cough and reducing co-occurring symptoms (dyspnea, cough, and fatigue) in patients with lung cancer.\n\nThe hypotheses are:\n\n1. Acupressure can alleviate cough in lung cancer survivors;\n2. Acupressure can reduce a cough-related symptom cluster (dyspnea-cough-fatigue) experienced by lung cancer survivors;\n3. Acupressure can reduce the symptom burden and improve the health-related quality of life and functional capacity of lung cancer survivors experiencing cough.\n\nParticipants will:\n\nReceive acupressure for 8 weeks or receive an education booklet; Keep a diary of their acupressure practice and symptoms; Be assessed at baseline (T0), early intervention (T1), post-intervention (T2), and 8 weeks after the intervention period (T3).",[595,596,597,598],"Lung Cancer (Diagnosis)","Acupressure","Coughing","Symptom Cluster",[596,600,341,601,598,602,603,604],"Cough","Dyspnea","Symptom Burden","Fatigue","Quality of Life",{"date":606,"type":38},"2026-05-22",{"date":608,"type":38},"2026-03-09",{"date":610,"type":22},"2027-02",{"name":44,"class":45},2,{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":192,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":621,"conditions":622,"keywords":626,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":46},"100639204","validation-of-the-cidi-50-against-the-scid-5-for-lifetime-mental-disorders-100639204","NCT07604753","Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders","Validity of the World Health Organization CIDI 5.0 for Assessing Lifetime Prevalence of Mental Disorders: A Clinical Reappraisal Study Using the SCID-5","Inclusion Criteria:\n\n* All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters\n* Live in the address sampled from the Census and Statistics Department List of Quarters\n* Reside in Hong Kong for at least six months in the past year\n* Able to read and communicate in Chinese or English\n* Without linguistic or cognitive difficulties\n\nExclusion Criteria:\n\n* Domestic workers",{"count":543,"type":22},"The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria.\n\nRecent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical \"gold standard\" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies.\n\nTherefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.",[623,624,625],"Major Depressive Disorder (MDD)","Generalized Anxiety Disorder (GAD)","Posttraumatic Stress Disorder (PTSD)",[627,628,629,630],"CIDI","Lifetime prevalence","Mental disorders","Clinical validation","2026-05-19",{"date":606,"type":38},{"date":634,"type":38},"2025-05-14",{"date":636,"type":22},"2028-01",{"name":44,"class":45},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":647,"briefSummary":648,"conditions":649,"keywords":651,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":659,"locationsCount":46},"100638400","mixed-method-evaulation-of-jockey-club-project-rebond-100638400","NCT07593534","Mixed Method Evaulation of Jockey Club Project ReBond","'Through the Gate' Desistance-Based Social Work Intervention for Offenders Serving First or Second Prison Sentence in Hong Kong - Jockey Club Project ReBond: A Longitudinal Mixed-Methods Randomised Control Trial","ReBond","Inclusion Criteria:\n\n* Hong Kong residents;\n* Aged 18 years or above and capable of providing informed consent\n* Serving a maximum of two sentences (including the current one) across any level or type of correctional facility\n* The current sentence lasts between 3 and 12 months.\n\nExclusion Criteria:\n\n* Physical conditions that preclude participation in at least 80% (six or seven sessions) of the Stage 1 in-prison workshops\n* Psychological conditions (e.g. bipolar disorder or schizophrenia) that preclude participation in at least 80% (six or seven sessions) of the Stage 1 in-prison workshops\n* Medical appointments that preclude participation in at least 80% (six or seven sessions) of the Stage 1 in-prison workshops\n* Inadequate Cantonese or English proficiency that prevent the individual from providing informed consent and participating in the Stage 1 group workshops\n* Cognitive impairments that prevent the individual from providing informed consent and participating in the Stage 1 group workshops\n* A history or high risk of inflicting physical harm on other participants, clinicians, or CSD staff",{"count":543,"type":22},[25],"Overall, the investigators hypothesize that participants assigned to the intervention group (Project ReBond) will demonstrate significantly greater improvements across all outcomes compared to the control group. Specifically, the investigators expect positive intervention effects on desistance and TPB outcomes to become evident as participants transition back into the community (i.e., across the at 1-2 months, 6-7 months, and 13-14 months post-release assessment waves), while workshop-specific outcomes will be evident at the end of the workshop.\n\nOverall Design The current study employs a two-arm, parallel-group randomized controlled trial (RCT) utilizing a mixed design. The between-subjects factor is the treatment condition (Project ReBond Intervention plus TAU versus TAU Control), and the within-subjects factor is time, with repeated measures assessed across multiple time points over a 13-month tracking period.\n\nIntervention Group (Project ReBond + TAU)\n\nParticipants allocated to the intervention group will receive the multifaceted Project ReBond services alongside standard care (TAU) for up to two years, beginning during their incarceration and continuing post-release. It should be noted that the 13-month research tracking period is shorter than the full two-year service duration; this truncated follow-up is necessary due to anticipated challenges in recruiting the predefined sample size before the project's overall deadline. The TAU is provided by the collaborating non-governmental organization (NGO), SideBySide. The Project ReBond intervention consists of the following specific components:\n\n* Pre-Release (During Incarceration): Each participant will receive a 6-session pro-social habit workshop and career-life counselling as part of their pre-release preparation. Those requiring employment assistance will be provided with job interview opportunities prior to their release.\n* Post-Release: Based on their personal interests and the recommendations of their caseworker, participants can choose to engage in the following services:\n\n  i) Subsidies for professional grooming and image building; ii) Peer mentorship provided by successful desisters; iii) Financial literacy training and counselling; iv) Ongoing career-life counselling; v) Routine workshops designed to cultivate and maintain pro-social hobbies; vi) Subsidies for further education or occupational training; vii) Family-based counselling involving the participant and their significant other(s); and viii) Volunteering and community outreach, sharing opportunities.\n\nTAU Control Group Participants in the control group will receive standard care (TAU) while incarcerated and remain free to utilize any existing social services post-release.",[650],"Recidivism",[652,296,653,654],"Desistance","Social Work","Theory of Planned Behaviour",{"date":606,"type":38},{"date":657,"type":38},"2026-04-16",{"date":42,"type":22},{"name":44,"class":45},""]